Oral corticosteroids for post-infectious cough in adults: study protocol for a double-blind randomized placebo-controlled trial in Swiss family practices (OSPIC trial)

Christoph Merlo, Stefan Essig, D Oana Brancati-Badarau, Jörg Daniel Leuppi, Benjamin Speich, Tobias E Erlanger, Lars G Hemkens, Andreas Zeller, Christoph Merlo, Stefan Essig, D Oana Brancati-Badarau, Jörg Daniel Leuppi, Benjamin Speich, Tobias E Erlanger, Lars G Hemkens, Andreas Zeller

Abstract

Background: Cough is a common reason for patients to visit general practices. So-called post-infectious cough is defined as lasting 3 to 8 weeks after an upper respiratory tract infection. It can be disabling in daily activities, with substantial impact on physical and psychosocial health, leading to impaired quality of life and increased health care costs. Recommendations for the management of post-infectious cough in primary care are scarce and incoherent. A systematic review and meta-analysis of randomized clinical trials (RCT) assessing patient-relevant benefits and potential harms of available treatments identified six eligible RCTs assessing different treatment regimens (i.e. inhaled fluticasone propionate, inhaled budesonide, salbutamol plus ipratropium-bromide, montelukast, nociception-opioid-1-receptor agonist, codeine, gelatine). No RCT found clear patient-relevant benefits and most had an unclear or high risk of bias. Post-infectious cough is thought to be mediated by inflammatory processes that are also present in exacerbations of asthma or chronic obstructive pulmonary diseases for which there is strong evidence that oral corticosteroids provide patient-relevant benefit without relevant harm. We therefore plan to conduct the first RCT evaluating the effectiveness of oral corticosteroids for post-infectious cough.

Methods: We are conducting a triple-blinded randomized-controlled and multicentred superiority trial in primary health care practices in Switzerland. We will include 204 adult patients who consult their general practitioner (GP) for a cough lasting 3 to 8 weeks following an upper respiratory tract infection. Participants will be randomly allocated to either the 5-day treatment with oral corticosteroids or placebo. The primary outcome is cough-related quality of life assessed by the Leicester Cough Questionnaire score 14 days after randomization. Secondary outcomes include cough-related quality of life at several time points, overall cessation of cough and adverse events.

Discussion: This RCT will provide evidence on whether oral corticosteroids are beneficial and safe in patients with post-infectious cough. Results can have a substantial impact on the well-being and management of these patients in Switzerland and beyond. An evidence-based treatment for this condition may reduce re-consultations with GPs and spending for antitussive drugs, thus possibly having an impact on health care spending.

Trial registration: ClinicalTrials.gov NCT04232449 . Prospectively registered on 18 January 2020.

Keywords: Adults; Corticosteroids; Post-infectious cough; Primary care; Quality of life; Randomized controlled trial.

Figures

Fig. 1
Fig. 1
Study schedule.*Clinical follow-up visits with the GP are at the discretion of the treating GP and/or based on the patient’s needs

References

    1. Rosendal M, Carlsen AH, Rask MT, Moth G. Symptoms as the main problem in primary care: a cross-sectional study of frequency and characteristics. Scand J Prim Health Care. 2015;33(2):91–99. doi: 10.3109/02813432.2015.1030166.
    1. French CT, Fletcher KE, Irwin RS. A comparison of gender differences in health-related quality of life in acute and chronic coughers. Chest. 2005;127(6):1991–1998. doi: 10.1378/chest.127.6.1991.
    1. Kardos P, Berck H, Fuchs KH, Gillissen A, Klimek L, Morr H, et al. Guidelines of the German Respiratory Society for diagnosis and treatment of adults suffering from acute or chronic cough. Pneumologie. 2010;64(11):701–711. doi: 10.1055/s-0030-1255526.
    1. Braman SS. Postinfectious cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 Suppl):138–146. doi: 10.1378/chest.129.1_suppl.138S.
    1. Bardin PG, Fraenkel DJ, Sanderson G, Lampe F, Holgate ST. Lower airways inflammatory response during rhinovirus colds. Int Arch Allergy Immunol. 1995;107(1–3):127–129. doi: 10.1159/000236951.
    1. Trigg CJ, Nicholson KG, Wang JH, Ireland DC, Jordan S, Duddle JM, et al. Bronchial inflammation and the common cold: a comparison of atopic and non-atopic individuals. Clin Exp Allergy. 1996;26(6):665–676. doi: 10.1111/j.1365-2222.1996.tb00593.x.
    1. Speich B, Thomer A, Aghlmandi S, Ewald H, Zeller A, Hemkens LG. Treatments for subacute cough in primary care: systematic review and meta-analyses of randomized clinical trials. Br J Gen Pract. 2018;68(675):e694–e702. doi: 10.3399/bjgp18X698885.
    1. Ponsioen BP, Hop WC, Vermue NA, Dekhuijzen PN, Bohnen AM. Efficacy of fluticasone on cough: a randomised controlled trial. Eur Respir J. 2005;25(1):147–152. doi: 10.1183/09031936.04.00053604.
    1. Pornsuriyasak P, Charoenpan P, Vongvivat K, Thakkinstian A. Inhaled corticosteroid for persistent cough following upper respiratory tract infection. Respirology. 2005;10(4):520–524. doi: 10.1111/j.1440-1843.2005.00732.x.
    1. El-Gohary M, Hay AD, Coventry P, Moore M, Stuart B, Little P. Corticosteroids for acute and subacute cough following respiratory tract infection: a systematic review. Fam Pract. 2013;30(5):492–500. doi: 10.1093/fampra/cmt034.
    1. Johnstone KJ, Chang AB, Fong KM, Bowman RV, Yang IA. Inhaled corticosteroids for subacute and chronic cough in adults. Cochrane Database Syst Rev. 2013;(3):CD009305. 10.1002/14651858.CD009305.pub2.
    1. Hay A, Little P, Harnden A, Thompson M, Wang K, Kendrick D, et al. Effect of oral prednisolone on symptom duration and severity in nonasthmatic adults with acute lower respiratory tract infection: a randomized clinical trial. JAMA. 2017;318(8):721–730. doi: 10.1001/jama.2017.10572.
    1. Hayward GN, Hay AD, Moore MV, Jawad S, Williams N, Voysey M, et al. Effect of oral dexamethasone without immediate antibiotics vs placebo on acute sore throat in adults: a randomized clinical trial. JAMA. 2017;317(15):1535–1543. doi: 10.1001/jama.2017.3417.
    1. Leuppi JD, Schuetz P, Bingisser R, Bodmer M, Briel M, Drescher T, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013;309(21):2223–2231. doi: 10.1001/jama.2013.5023.
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586. doi: 10.1136/bmj.e7586.
    1. McAllister WA, Winfield CR, Collins JV. Pharmacokinetics of prednisone in normal and asthmatic subjects in relation to dose. Eur J Clin Pharmacol. 1981;20:141–145. doi: 10.1007/BF00607151.
    1. Morice AH, McGarvey L, Pavord I. Recommendations for the management of cough in adults. Thorax. 2006;61(Suppl I):i1–i24. doi: 10.1136/thx.2006.065144.
    1. Schupp JC, Fichtner UA, Frye BC, Heyduck-Weides K, Birring SS, Windisch W, et al. Psychometric properties of the German version of the Leicester Cough Questionnaire in sarcoidosis. PLoS One. 2018;13(10):e0205308. doi: 10.1371/journal.pone.0205308.
    1. Ward N. The Leicester Cough Questionnaire. J Physiother. 2016;62(1):53. doi: 10.1016/j.jphys.2015.05.011.
    1. Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MDL, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ) Thorax. 2003;58(4):339–343. doi: 10.1136/thorax.58.4.339.
    1. Berkhof FF, Boom LN, ten Hertog NE, Uil SM, Kerstjens HAM, van den Berg JWK. The validity and precision of the Leicester Cough Questionnaire in COPD patients with chronic cough. Health Qual Life Outcomes. 2012;10(1):4. doi: 10.1186/1477-7525-10-4.
    1. WHO-UMC (World Health Organization-Uppsala Monitoring Centre). 2017. . Accessed 19 Oct 2017.
    1. Raj AA, Pavord DI, Birrig SS. What is the minimal important difference for the Leicester Cough Questionnaire? In: Chung KF, Widdicombe JG, editors. Pharmacology and therapeutics of cough. Berlin: Springer; 2009. pp. 311–320.
    1. Wang K, Birrig SS, Taylor K, Fry NK, Hay AD, Moore M, et al. Montelukast for postinfectious cough in adults: a double-blind randomized placebo-controlled trial. Lancet Respir Med. 2014;2(1):35–43. doi: 10.1016/S2213-2600(13)70245-5.
    1. Waljee AK, Rogers MAM, Lin P, Singal AG, Stein JD, Marks RM, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. doi: 10.1136/bmj.j1415.
    1. World Health Organization (WHO) Statement on the second meeting of the International Health Regulations (2005) emergency committee regarding the outbreak of novel coronavirus (2019-nCoV) Geneva: WHO; 2020.
    1. World Health Organization (WHO) Coronavirus disease 2019 (COVID-19) situation report - 71. Geneva: WHO; 2020.
    1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.
    1. International council for harmonisation of technical requirements for pharmaceuticals for human use (ICH). ICH harmonised guideline: integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2). 2016. . Accessed 28 May 2020.
    1. International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. Statistical principles for clinical trials, E9, Step 4. ICH harmonized tripartite guideline. 1998. . Accessed 28 May 2020.
    1. Ryan H, Trosclair A, Gfroerer J. Adult current smoking: differences in definitions and prevalence estimates. J Environ Public Health. 2012;2012:918368. doi: 10.1155/2012/918368.
    1. Hernan MA, Robins JM. Per-protocol analyses of pragmatic trials. N Engl J Med. 2017;377(14):1391–1398. doi: 10.1056/NEJMsm1605385.
    1. European Medicines Agency. EMA. Guideline on Missing Data in Confirmatory Clinical Trials. Committee for Medicinal Products for Human Use (CHMP). 2010. Doc. Ref. EMA/CPMP/EWP/1776/99 Rev.1. . Accessed 27 May 2020.
    1. van Buuren S, Groothuis-Oudshoorn K. Mice: multivariate imputation by chained equations in R. J Stat Softw. 2011;45(3):1–68. doi: 10.18637/jss.v045.i03.
    1. United States Department of Health and Human Services. Common terminology criteria for adverse events. CTCAE, Version 5.0. 2017. . Accessed 28 May 2020.
    1. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013;158(3):200–207. doi: 10.7326/0003-4819-158-3-201302050-00583.
    1. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ. 2014;348:g1687. doi: 10.1136/bmj.g1687.
    1. Schulz KF, Altman DG, Moher D, CONSORT Group CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18. doi: 10.1186/1741-7015-8-18.
    1. Madison MJ, Irwin RS. Cough: a worldwide problem. Otolaryngol Clin N Am. 2010;43:1–13. doi: 10.1016/j.otc.2009.11.001.
    1. International Committee of Medical Journal Editors. Defining the role of authors and contributors. . Accessed 17 Jun 2020.
    1. Schappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02. National Center for Health Statistics. Vital Health Stat. 2006;13(159):1–66.
    1. Birrig SS. Developing antitussives: the ideal clinical trial. Pulm Pharmacol Ther. 2009;22(2):155–158. doi: 10.1016/j.pupt.2008.10.012.
    1. Morice AH, McGarvey L, Pavord I. British Thoracic Society Cough Guideline Group. Recommendations for the management of cough in adults. Thorax. 2006;61(Suppl 1):i1–24. doi: 10.1136/thx.2006.065144.
    1. Kardos P, Dinh QT, Fuchs KH, Gillissen A, Klimek L, Koehler M, et al. German Respiratory Society guidelines for diagnosis and treatment of adults suffering from acute, subacute and chronic cough. Respir Med. 2020. 10.1016/j.rmed.2020.105939.
    1. Voelker R. Boxed warning for allergy drug. JAMA. 2020;323(13):1236.
    1. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2017 Report. Global Initiative for Chronic Obstructive Lung Disease 2017. . Accessed 28 May 2020.
    1. O'Grady KF, Grimwood K, Torzillo PJ, Rablin S, Lovie-Toon Y, Kaus M, et al. Effectiveness of a chronic cough management algorithm at the transitional stage from acute to chronic cough in children: a multicenter, nested, single-blind, randomised controlled trial. Lancet Child Adolesc Health 2019;3(12):P889–898.
    1. Federal Office for Public Health (Bundesamt für Gesundheit). So Schützen Wir Uns. 2020. . Accessed 27 May 2020.
    1. Thornton J. Clinical trials suspended in UK to prioritize covid-19 studies and free up staff. BMJ. 2020;368:m1172. doi: 10.1136/bmj.m1172.
    1. Spinou A, Birring SS. An update on measurement and monitoring of cough: what are the important study endpoints? J Thorac Dis. 2014;6(Suppl 7):S728–S734.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅